On May 12, 2021, InBios announced that it had received Emergency Use Authorization from the U.S. Food and Drug Administration for its SCoV-2 Ag Detect Rapid Test.

The clinical performance of SCoV-2 Ag Detect Rapid Test was evaluated in a multi-site prospective study in the U.S., which showed that the test accurately determined 86.67% of those who were positive (PPA) and 100% of those who were negative (NPA) for SARS-CoV-2.